In the coming years the continuous glucose monitoring systems products market is expected to reach USD12,835.6 million by 2025 and is expected to steadily grow at a CAGR of 15.7% to reach USD 55,048.4 million by 2035. In 2024, continuous glucose monitoring systems have generated roughly USD 11,096.4 million in revenues.
Continuous Glucose Monitoring (CGM) devices are transforming the lives of people with diabetes. These smart devices track blood glucose levels continuously, reminding users around the clock. The CGM system is a tiny sensor that is implanted beneath the skin and measures glucose in interstitial flui,d and sends it to a connected device like a smartphone or an insulin pump.
Through the tracking of this continuous feedback, individuals will have better choices about lifestyle with what they eat, how their bodies move, and how they modulate insulin levels.
CGM usage growth is mainly caused by increasing numbers of people who have diabetes and an escalating desire for better glucose control. With ongoing technological improvements, CGMs are now smaller, more convenient, and more precise, with diminutive-sized sensors and enhanced integration into mobile devices and insulin pumps.
Patients are becoming more knowledgeable about how CGMs reduce the frequency of hypoglycemic events and improve the long-term management of the disease. Furthermore, the shift to personalized medicine and greater coverage through insurance has reduced the cost element and made devices affordable and desirable. Thus, more and more people are embracing CGMs as part of diabetes management more efficiently and precisely..
The expansion of Continuous Glucose Monitoring (CGM) systems from 2020 to 2024 has been fueled by factors such as the increasing number of patients with diabetes and the technological advancements in certain products, which have made its use more convenient for everyday use.
New technologies have increasingly made CGMs more convenient to use. Devices now easily synchronize with smartphones and insulin pumps, offering a more connected and tailored diabetes management system. Real-time alerts, prediction features, and extended sensor duration make the CGM even more convenient and reliable for consumers.
Ahead of us, there are indications that CGMs will only become more popular for type 1 and type 2. Developing AI and machine learning technology may transform their predictive capabilities and enable even more preventive care. As costs fall and insurance begins to cover more, these products will be accessible to more and more individuals so that everyone has access to this revolutionary technology.
Explore FMI!
Book a free demo
The increasing number of diabetes, most notably type 2 diabetes, has directly pushed the demand for improved management technologies. More and more people developing diabetes from changed lifestyles mean never before have they needed such consistent and timely feedback on blood glucose levels. All these have improved the devices' attractiveness to a wider population, from children to older adults.
Thirdly, enhanced insurance coverage for CGM systems has rendered them more affordable. With insurers increasingly appreciating the importance of CGMs in averting complications and guiding diabetes management, an increasing number of patients can now afford the devices.
Furthermore, public health efforts and increased awareness of the benefits of CGMs have further promoted their use. With these elements combined, CGM systems are becoming essential to diabetes care throughout North America.
The ever-increasing burden of diabetes has made it one of the most complicated health issues in the region. CGMs empower patients to explicitly monitor glucose levels at all times, thereby minimizing variations and, over time, improving outcomes. The correlation between aging and diabetes brings with it an increased demand for control in the form of devices that specify glucose levels.
This explains why developed healthcare systems such as Europe have been able to advance the engagement of CGMs. Public healthcare set-ups of Germany, France, and the UK have developed in tandem with the necessity to highlight CGMs in lowering complications and improving the quality of life of diabetics. For people across Europe, insurance coverage for CGMs has greatly enhanced accessibility features of the technology for people with diabetes.
The rapidly growing disease burden and related complications caused by diabetes throughout the continent. CGMs are available to any patient and provide these patients with the ability to monitor glucose levels thereby reducing fluctuations and ultimately improving long-term outcomes. With the trend of increasing diabetics aging in society, device demand for better control of glucose levels rises.
Advanced and developed healthcare systems such as Europe have greatly supported the use of CGMs. The public healthcare set-ups of Germany, France, and the UK have been increasingly keen on the importance of using CGMs in reducing complications and improving the quality of life among diabetic patients.
Insurance coverage across most of Europe for CGMs has enhanced accessibility for the use of such technology among a wide range of people with diabetes.
Rapid urbanization and the burgeoning number of people living sedentary lifestyles are all driving factors for the increasing prevalence of diabetes. This gives rise to an escalating demand for the efficient monitoring needed by patients through such devices as continuous glucose monitors (CGMs).
The monitors assist the patients in continuously monitoring their blood glucose levels and obtaining real-time information to avert hazardous fluctuations and long-term complications.
The developed healthcare infrastructure in the region has made these CGMs available. Urban areas, in particular, have a high prevalence of use in CGMs, with the more expansive healthcare centers and specialized clinics providing CGM services. Increased emphasis on preventative medicine and personalized treatment is prompting more individuals to utilize CGM systems as part of their diabetes care.
Governmental initiatives aimed at controlling the diabetes epidemic have rendered CGMs cheaper and educated more people about them. Such initiatives, and advanced CGM technologies, have made them cheaper, more accurate, and user-friendly, thus multiplying the penetration of the systems throughout the region.
Higher Costs Associated with Products and Maintenance are Creating Barriers in Product Adoption
In nations with less extensive healthcare coverage, patients cannot easily access these systems due to their higher price range. Though some countries in the region have added CGMs to their health plans, the payment policies are restricted, and in most cases, the cost remains a burden for individuals.
The problem is one of the constraints against the large-scale use of CGMs, particularly in areas where diabetes technology is not widely available. Until costs become more reasonable or insurance coverage becomes more prevalent, the adoption rate of CGMs will be constrained for most people who would gain from them.
Emphasis on Developing Devices for Paediatric and Elderly Population can bring New Business Opportunities to the Players.
Focusing on Continuous Glucose Monitoring (CGM) device customization for kids and the elderly represents to manufacturers an important means of making the market brighter and meeting the exclusive necessities of these ages.
To make wearing a CGM sensor less troublesome, manufacturers can exploit child-friendly products that include basic functions, child safety mechanisms, and products, like nebulizers, that are appropriate for the younger demographic. Aside from safety function considerations, developers can increase market accessibility by offering unique designs such as stylish and discreet and features connecting the sensors to the app that allow for notifications for parents.
When it comes to the elderly and their issues with reduced dexterity, sight limitations, or cognitive problems, manufacturers may consider incorporating CGMs designed to compensate for these challenges. These devices might include larger screens, less complex controls, and even the use of voice prompts to simplify the process of monitoring glucose for elderly people. Also, with the caregiver alerts and family-member-involving, the safety of the patient is guaranteed, and peace of mind is provided.
The specific targeting of these two groups with unique wants besides the general concern over diabetes management and new spaces for business progress is an absolute plus. The world demographic changes and the rise in kids diagnosed with diabetes mean that the manufacturers of CGM will make a long-term profit only if they focus on these segments.
Such a strategy is a way of addressing the issue of access and client perceived quality of life, groups that are in a precarious situation, which in turn translates today into the opportunity for manufacturers in the diabetes care market to pursue the most profitable products.
CGM system markets are moving fast, propelled by technology changes and patient-centric care approaches. Among the most striking changes in the CGM system are the minimally invasive and even non-invasive CGM device development, which tend to be more comfortable during monitoring and enhance user compliance.
Integrated systems are also emerging, as CGM systems are combined with insulin delivery devices to ease diabetes management with automated insulin dosing more accurately. Another trend worth mentioning is wearable technology, which provides continuous health monitoring for the user, with easy data sharing with healthcare providers.
It will enhance data analysis and provide predictive insight from artificial intelligence, demonstrating how far-reaching these technologies can be. All these developments are ushering in more user-friendly and powerful solutions for diabetic management, empowering users increasingly to take charge of their health.
Overshadowed by the emerging trend of increasing OTC CGM devices gaining popularity in the CGM market is an increasing number of consumer offerings that provide real-time glucose information, allowing for monitoring, thus reducing the need for a prescription.
Abbott Laboratories, for example, launched the Lingo CGM system in September 2024 for continuous glucose monitoring. Another party in the increasing interest in tracking glucose levels for general health and wellness among those without glucose disorders is being attracted more actively.
This trend is lifting the market beyond diabetes and drawing a healthier demographic into it. Moreover, there is also suggestive going towards the incorporation of smart connectivity in CGM systems, coupling them with smartphones and cloud platforms to facilitate remote access for healthcare professionals to monitor different patient data.
There is also revolutionizing the very functionality of CGM systems by machine learning and artificial intelligence, providing users with personalized insights and predictive analytics to manage their glucose levels properly. These are shaping a more accessible, personalized future for glucose monitoring.
The incrementing of use of Continuous Glucose Monitoring (CGM) systems from 2020 to 2024 was the result of the ascendant of diabetes normalization and the desire for more accurate, moment blood glucose tracking. CGM technology was predominantly used by patients with Type 1 and Type 2 diabetes to achieve better glucose control and reduce the complications that appeared due to the changes in blood sugar levels.
This interest was also ignited by the more and more observed awareness concerning early diabetes detection and management, which gradually became one of the crucial topics of public awareness about health.
The progressive availability of more cost-efficient and user-friendly CGM devices with the inclusion of smartphone and insulin pump linkage opened the group to a wider range of patients. Still, with the issues of high prices and the lack of insurance coverage, it was a long way to go, especially in developing countries.
When we analyze the years 2025 to 2035, the CGM market is going to be influenced by the AI power tools that will be utilized in the analytics field, thus the target of analyzing the glucose trends and suggesting the probable phases.
The assimilation of CGMs and wearable technology, as well as the introduction of mobile apps, will be the backbone of the manufacturer's effort to improve the customer experience, which will be conducive to the obtaining of a better human management of diabetes.
The research regarding CGMs for non-diabetic groups, e.g. the pre-diabetics and people with a metabolic syndrome, would be a stimulus for the opening of new markets. The improved coverage of insurance and the incentives of the government will continue to be the main drivers of user adoption.
At the same time, manufacturers' attempts to lower purchase costs will help to solve the issue of the existing price barrier. Furthermore, the new technologies will be the non-invasive monitoring technologies, the more accurate sensors, and the longer-lasting devices for a better patient experience and increased market demand.
| Category | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Regulatory Landscape Strictly applies FDA and CE regulatory approval for CGM devices, underscoring the importance of accuracy and application for integration with insulin pumps. |
| Technological Advancements | Technological Advances Integration with smartphones and insulin pumps |
| Consumer Demand | Consumer Demand There is an Increasing preference toward on-demand glucose monitoring instead of traditional fingerstick testing. |
| Market Growth Drivers | Rising diabetes prevalence, increasing awareness of CGM benefits, and wearable technologies. |
| Sustainability | Limited focus on sustainability; reliance on disposable sensors and plastic-intensive device components. |
| Supply Chain Dynamics | Dependence on specialized sensor manufacturers; occasional shortages due to semiconductor supply constraints. |
| Category | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Regulatory adaptations must keep pace with AI-based CGM analytics, non-invasive glucose monitoring, and broadened indications. |
| Technological Advancements | Cloud-based diabetes management platforms for non-invasive glucose monitoring; AI-augmented predictive analytics; biodegradable CGM sensors with extended wearability. |
| Consumer Demand | Increased adoption for metabolic health tracking, fitness monitoring, and introduction into emerging markets. |
| Market Growth Drivers | Personalized medicine, AI glucose management, and regulatory support toward open accessibility. |
| Sustainability | Development of biodegradable sensors, recyclable device packaging, and energy-efficient CGM systems. |
| Supply Chain Dynamics | Regionalized production, diversification of suppliers, and increased automation in CGM manufacturing. |
Market Overview
The increasing number of chronic wounds, radiation damage, and neurological disorders is fueling sharply rising United States sales of hyperbaric oxygen therapy equipment. The increasing demographic number and augmented constituent of diabetes are driving higher demand for HBOT in the healing of diabetic foot ulcers.
Advances in technology in the form of portable and multi-place hyperbaric chambers are also propelling the market.It is increasingly used for military and sports medicine applications due to HBOT's therapeutic benefits in managing TBI and sports injuries.
Reimbursement-driven uses with FDA-approved applications such as carbon monoxide poisoning, decompression sickness, and gas embolism treatments are also picking up. Market growth is inhibited due to the high equipment price, regulation, and reimbursement. However, the increasing demand for the benefit of HBOT in stroke rehabilitation and post-COVID-19 illness is expected to drive consistent market growth.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 11.9% |
Market Outlook
Germany has been the latest country to adopt the Continuous Glucose Monitoring (CGM) technology which is powered by a powerful health care system that concentrates on modernization and patient-centered care. The nation’s dedication to preventive healthcare and the management of chronic conditions, which include diabetes, has stimulated a healthy setting for the use of CGM technology. Additionally, Germany's very favorable reimbursement policies are the ones which make it easier to access CGMs for patients.
A surge in awareness of the benefits of continuous glucose monitoring, which is the real titan of this trend, has consequently enhanced glucose metabolism and quality of life. The emergence of new technologies has also added the benefit of making CGMs more efficient, affordable, and user-friendly. This, in turn, has caused them to be adopted at an even greater rate.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 9.3% |
Market Outlook
The rise of diabetes in India, with a surge in demand for continuous glucose monitoring systems, especially among younger generations, is the current trend. The country’s promotion of digital healthcare solutions in cities is a major factor in the accessibility of continuous glucose monitoring systems (CGMs).
In contrast to the situation in rural areas, initiatives focusing on cost-efficiency are the driving force behind the device’s more widespread adoption. The government’s attempt to relieve diabetes and CGM’s incessant message about the advantages of continuous monitoring are why CGMs are increasingly popular in India. As India’s middle class grows, there is a CGM manufacturer that will capitalize on its expanding market.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 17.2% |
Market Outlook
According to the latest report from the Preventive Health Network, type 2 diabetes is a serious public health challenge facing China. In pursuing improved health and diabetes rareness, many individuals are trying out solutions like the CGM. To a reasonable degree, the government's move to be more accountable and to embrace advanced technology is a precursor to the adoption of CGM.
Although these devices are high-end products, domestic production capabilities and healthcare partnerships would make the devices more cost-friendly and more available in the urban areas, allowing a larger number of people to use the technology.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 17.8% |
Market Outlook
The upturn in the age of the Japanese population and type 2 diabetes symptoms are major factors in the rise of the demand for professional continuous glucose monitoring systems in Japan. Japan, being one of the world's foremost experts in healthcare innovation, uses CGMs more often for the enhancement of diabetes care.
In addition to the country's healthcare system that guarantees the accessibility of these devices to patients, Japan's healthcare network provides these devices to patients through insurance.
Amid the trend of precision medicine, disease management, and preventive care, Japan is planning to witness a continuous increase in its market for CGM. Together with the high-tech healthcare environment in Japan, all of these changes ensure that CGM technology will be significantly seen in future diabetes management strategies.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 8.1% |
The Central Role Played by Sensors in Providing Accurate real-time glucose Readings aid to hold Dominant Position in the Market.
Sensors control the Continuous Glucose Monitoring (CGM) systems market as they are the most significant element that needs to measure glucose levels accurately within the interstitial fluid. Sensors constantly monitor glucose variability in real time and give timely information that helps patients control diabetes better. It is the focal point of CGM systems and is a key factor for appropriate glucose control.
With the improvement of technology, sensor performance has dramatically improved with higher accuracy, longer wear durations, and enhanced comfort. As diabetes becomes more prevalent worldwide and the demand for customized diabetes management increases, high-quality, consistent sensors have seen increased demand, rendering them the largest and most rapidly growing segment of the CGM market.
Growing Technological Advancements in Sensor Further Anticipate its Market Growth.
Increasing advancements in sensor technology are expected to anticipate the growth of continuous glucose monitoring systems. These advancements aim to improve the overall user experience, guaranteeing consistent, and real-time glucose monitoring. With greater accuracy, sensors optimize diabetes care, decrease complications, and enhance patient outcomes.
Their increased lifespan and compatibility with other devices, such as insulin pumps and smartphones, also ensure robust cost-effectiveness and convenience, leading to high adoption rates and market growth.
Home Care Diagnostics segment dominates the Continuous Glucose Monitoring (CGM) systems market.
The Home Care Diagnostics device business sector leads the Continuous Glucose Monitoring (CGM) systems market. The reason behind it is mostly because of the emerging trend towards home-based and distant monitoring of diabetes. With more diabetic patients looking to self-test and self-manage from their homes, the CGMs are now an indispensible gadget for managing diabetes at home.
Patients can monitor their glucose levels in real time, change their insulin or diet to match, and decrease the number of doctor visits they need.
Convenience and Accessibility of Home-care Diagnostic Devices Anticipates Industry Further Growth
The main reason behind the increasing popularity of CGMs is their convenience and accessibility, especially in home diagnostics. With the help of these sensors, people with diabetes no longer have to go back and forth to the hospital for regular checks or endure those painful and time-consuming finger-stick tests to check their blood sugar levels.
CGMs provide continuous, real-time glucose data, which has allowed many people to monitor their blood sugar levels not only at home but also at any time. This autonomy and instantaneous feedback drive the patients to become more educated in managing their diabetes.
By introducing a non-invasive and convenient facility, CGMs enable reliable and accurate glucose monitoring, thus facilitating the blood sugar regulation system for improving patient outcomes in the long term.
One major reason behind the expansion of the Continuous Glucose Monitoring (CGM) market is that people are becoming more knowledgeable about the benefits of real-time glucose monitoring, the increasing incidence of diabetes, and the ongoing introduction of CGM.
With the rise in the need for personalized diabetes management, we are now entering the age of next-generation CGM systems, which is marked by their precise consistency, long battery life, and wireless, lightweight integration with cell phones and insulin pumps.
On the other hand, the market is overfilled with competitors, as well as the classic companies of the medical device industry, new companies recognized for their innovation and striving to grab the piece of market share, to become an alternative to the established companies.
The regulatory approval processes and the increased number of healthcare partnerships will play a huge role in the achievement of the company's competitive advantage. Better technology will cause a further increase in competition among companies. They will fight more to give more economical, efficient, and user-friendly CGM solutions that will meet the demands of diabetic patients.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Abbott Laboratories | 55.2% |
| Dexcom, Inc. | 26.5% |
| Medtronic plc | 15.7% |
| Senseonics Holdings, Inc. | 0.23% |
| Other Companies (combined) | 2.4% |
| Company Name | Key Company Offerings and Activities |
|---|---|
| Dexcom, Inc. | Specializes in real-time CGM systems with advanced connectivity and accuracy. |
| Abbott Laboratories | Develops Freestyle Libre CGM devices focusing on affordability and ease of use. |
| Medtronic plc | Offers integrated CGM and insulin pump systems for advanced diabetes management. |
| Senseonics Holdings, Inc. | Provides implantable CGM systems with extended wear duration. |
Key Company Insights
Dexcom, Inc. (26.5%)
Dexcom leads the CGM market with highly accurate real-time glucose monitoring systems featuring seamless smartphone connectivity and AI-driven analytics.
Abbott Laboratories (55.2%)
Abbott’s FreeStyle Libre series has revolutionized the CGM space by offering affordable, sensor-based monitoring solutions with growing adoption worldwide.
Medtronic plc (15.7%)
Medtronic integrates CGM with insulin delivery systems, enhancing personalized diabetes care through closed-loop technologies.
Senseonics Holdings, Inc. (0.2%)
Senseonics is gaining traction with implantable CGM systems offering extended wear and reduced sensor replacement frequency.
Several other companies contribute significantly to the CGM market by developing innovative solutions and expanding their global reach. They include:
The overall market size for continuous glucose monitoring systems market was USD 12,835.6 million in 2025.
The continuous glucose monitoring systems market is expected to reach USD 55,048.4 million in 2035.
Rising cases of chronic wound as well as rise in adoption in private sector has significantly increased the demand for continuous glucose monitoring systems.
The top key players that drives the development of continuous glucose monitoring systems market are Abbott Laboratories, Dexcom, Inc., Medtronic plc, Senseonics Holdings, Inc. and SIBIONICS
Sensors by component in continuous glucose monitoring systems market is expected to command significant share over the assessment period.
Cancer Biopsy Market – Growth & Technological Innovations 2025 to 2035
Cannabis Use Disorder Treatment Market – Trends & Innovations 2025 to 2035
Water Testing Kit Market Analysis by Product, Test Type, Water Type, End User, and Region - Analysis for 2025 to 2035
Yeast Infection Treatment Market by Drug Type, Distribution Channel, End User, and Region, 2025 to 2035
Walking Aid Market Analysis by Product, Technology, End-user, and Region 2025 to 2035
Burns Treatment Market Overview – Growth, Demand & Forecast 2025 to 2035
Continuous Glucose Monitoring Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
